Biochemical and pharmacologic studies with 1- -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D002264:Carboxylic Acids / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell; D002460:Cell Line / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects; D003516:Cycloparaffins / Q000494:pharmacology*; D003561:Cytarabine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000494:pharmacology* / Q000652:urine; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003641:Deamination; D003692:Delayed-Action Preparations; D003864:Depression, Chemical; D006207:Half-Life; D000882:Haplorhini; D006801:Humans; D006868:Hydrolysis; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D009363:Neoplasm Proteins / Q000096:biosynthesis; D010830:Physostigmine; D010949:Plasma; D012334:RNA, Neoplasm / Q000096:biosynthesis; D014316:Tritium; D014529:Uridine
D000970:Antineoplastic Agents; D002264:Carboxylic Acids; D003516:Cycloparaffins; D004273:DNA, Neoplasm; D003692:Delayed-Action Preparations; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D003561:Cytarabine; D014316:Tritium; D010830:Physostigmine; D014529:Uridine